Simvastatin improves olanzapine-induced dyslipidemia in rats through inhibiting hepatic mTOR signaling pathway

LXRɑ participates in the mTOR/S6K1/SREBP-1c signaling pathway during sodium palmitate-induced lipogenesis in HepG2 cells

(2018) Youping Zhou et al.   Nutrition & Metabolism

TOR Signaling and Nutrient Sensing

(2016) Thomas Dobrenel et al.   Annual Review of Plant Biology

The Mechanistic Target of Rapamycin: The Grand ConducTOR of Metabolism and Aging

(2016) Brian K. Kennedy et al.   Cell Metabolism

Effects of Ezetimibe, Simvastatin, and their Combination on Inflammatory Parameters in a Rat Model of Adjuvant-Induced Arthritis

(2016) Carmem Patrícia Barbosa et al.   INFLAMMATION

Flavanol-rich lychee fruit extract alleviates diet-induced insulin resistance via suppressing mTOR/SREBP-1 mediated lipogenesis in liver and restoring insulin signaling in skeletal muscle

(2016) Hung-Wen Liu et al.   MOLECULAR NUTRITION & FOOD RESEARCH

Ameliorating antipsychotic-induced weight gain by betahistine: Mechanisms and clinical implications

(2016) Jiamei Lian et al.   PHARMACOLOGICAL RESEARCH

Acute effects of oral olanzapine treatment on the expression of fatty acid and cholesterol metabolism-related gene in rats

(2015) Xuemei Liu et al.   LIFE SCIENCES

A clerodane diterpene inhibit adipogenesis by cell cycle arrest and ameliorate obesity in C57BL/6 mice

(2015) Muheeb Beg et al.   MOLECULAR AND CELLULAR ENDOCRINOLOGY

Betahistine co-treatment ameliorates dyslipidemia induced by chronic olanzapine treatment in rats through modulation of hepatic AMPKα-SREBP-1 and PPARα-dependent pathways

(2015) Xuemei Liu et al.   PHARMACOLOGICAL RESEARCH

Comparison of rhBMP-2 versus Autogenous Iliac Crest Bone Graft for 2-Level Anterior Cervical Discectomy and Fusion for Cervical Spondylotic Myelopathy

(2015) Bingyi Tan et al.   MEDICAL SCIENCE MONITOR

Diacylglycerol kinase-ζ regulates mTORC1 and lipogenic metabolism in cancer cells through SREBP-1

(2015) P Torres-Ayuso et al.   Oncogenesis

Decreased exposure of simvastatin and simvastatin acid in a rat model of type 2 diabetes

(2014) Dan Xu et al.   ACTA PHARMACOLOGICA SINICA

Antipsychotics use in children and adolescents: An on-going challenge in clinical practice

(2014) Carolina Schneider et al.   JOURNAL OF PSYCHOPHARMACOLOGY

The pharmacology of statins

(2014) Cesare R. Sirtori   PHARMACOLOGICAL RESEARCH

Cardiovascular effects of statins, beyond lipid-lowering properties

(2014) Christos G. Mihos et al.   PHARMACOLOGICAL RESEARCH

Hepatic mTORC1 controls locomotor activity, body temperature, and lipid metabolism through FGF21

(2014) M. Cornu et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Lovastatin for the adjunctive treatment of schizophrenia: A preliminary randomized double-blind placebo-controlled trial

(2014) Ahmad Ghanizadeh et al.   PSYCHIATRY RESEARCH

Betahistine ameliorates olanzapine-induced weight gain through modulation of histaminergic, NPY and AMPK pathways

(2014) Jiamei Lian et al.   PSYCHONEUROENDOCRINOLOGY

Primary prevention of cardiovascular events in patients with major mental illness: a possible role for statins

(2013) Chittaranjan Andrade   BIPOLAR DISORDERS

mTOR in aging, metabolism, and cancer

(2013) Marion Cornu et al.   CURRENT OPINION IN GENETICS & DEVELOPMENT

Phospho-mTOR: A novel target in regulation of renal lipid metabolism abnormality of diabetes

(2013) Jun Hao et al.   EXPERIMENTAL CELL RESEARCH

Metabolic syndrome and antipsychotic monotherapy treatment among schizophrenia patients in Malaysia

(2013) Mas Ayu Said et al.   PREVENTIVE MEDICINE

mTOR Signaling in Growth Control and Disease

(2012) Mathieu Laplante et al.   CELL

Reducing olanzapine-induced weight gain side effect by using betahistine: a study in the rat model

(2012) Chao Deng et al.   JOURNAL OF PSYCHOPHARMACOLOGY

Alterations to Melanocortinergic, GABAergic and Cannabinoid Neurotransmission Associated with Olanzapine-Induced Weight Gain

(2012) Katrina Weston-Green et al.   PLoS One

mTOR Complex 1 Regulates Lipin 1 Localization to Control the SREBP Pathway

(2011) Timothy R. Peterson et al.   CELL

Effects of olanzapine on muscarinic M3 receptor binding density in the brain relates to weight gain, plasma insulin and metabolic hormone levels

(2011) Katrina Weston-Green et al.   EUROPEAN NEUROPSYCHOPHARMACOLOGY

Olanzapine treatment and metabolic dysfunction: a dose response study in female Sprague Dawley rats

(2010) Katrina Weston-Green et al.   BEHAVIOURAL BRAIN RESEARCH

Comparison of Effects of Simvastatin Versus Atorvastatin on Oxidative Stress in Patients With Coronary Heart Disease

(2010) Jia Li et al.   CLINICAL CARDIOLOGY

Effectiveness of Medications Used to Attenuate Antipsychotic-Related Weight Gain and Metabolic Abnormalities: A Systematic Review and Meta-Analysis

(2010) Lawrence Maayan et al.   NEUROPSYCHOPHARMACOLOGY

Pharmacological Management of Atypical Antipsychotic-Induced Weight Gain

(2009) Trino Baptista et al.   CNS DRUGS

An Emerging Role of mTOR in Lipid Biosynthesis

(2009) Mathieu Laplante et al.   CURRENT BIOLOGY

Sensitivity of the female rat to olanzapine-induced weight gain—Far from the clinic?

(2009) Katrina Weston-Green et al.   SCHIZOPHRENIA RESEARCH

Rapamycin down-regulates LDL-receptor expression independently of SREBP-2

(2008) Laura J. Sharpe et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

Liver X Receptors (LXR) as Therapeutic Targets in Dyslipidemia

(2008) Jerzy Bełtowski   Cardiovascular Therapeutics

Olanzapine: review of safety 2008

(2008) Joshua T Kantrowitz et al.   Expert Opinion On Drug Safety

Antipsychotic-induced body weight gain: Predictors and a systematic categorization of the long-term weight course

(2008) Stefan Gebhardt et al.   JOURNAL OF PSYCHIATRIC RESEARCH

Secondary Effects of Antipsychotics: Women at Greater Risk Than Men

(2008) M. V. Seeman   SCHIZOPHRENIA BULLETIN

Dose translation from animal to human studies revisited

(2007) Shannon Reagan-Shaw et al.   FASEB JOURNAL